Daily Brief Health Care: Iqvia Holdings, Grifols SA, Basilea Pharmaceutica Ag, Spruce Biosciences and more

• Back in 2016, IMS Health and Quintiles went through a merger of equals to form “QuintilesIMS” which was later renamed to be “IQVIA” in 2017.
• “I” and “Q” stand for IMS Health and Quintiles respectively and “VIA” means “by way of”.
• Since IMS and Quintiles both used to be separate public companies, let me discuss these two businesses separately at first before getting into the details of their post-merger status.

• Gotham City Research’s short report on Grifols is seen as misguided, creating a buying opportunity for investors
• Grifols is still viewed as a strong business with potential for significant growth in the next 12-18 months
• With COVID headwinds normalizing and a new management team in place, Grifols is expected to see a 140% increase in stock price if it trades at historical average EBITDA multiple, making it a compelling long opportunity

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the remaining drug candidate from its oncology portfolio. Basilea’s other oncology assets were offloaded in 2022 (for initial consideration of CHF15m) following the company’s decision to right-size and focus exclusively on its anti-infectives franchise. Lisavanbulin is a tumour checkpoint controller and was being evaluated as a treatment for glioblastoma before Basilea decided to cease development following the strategic pivot. The initial purchase price is undisclosed, although Basilea will be eligible for a fixed double-digit share of any subsequent commercial partnerships.

• SPRB is developing tildacerfont, a second-generation CRF1 antagonist for CAH treatment
• Recent Phase 2 trial failure doesn’t negate potential, but upcoming trial results are more relevant
• Market overreaction to negative news creates attractive opportunity for investors, with upside potential and downside protection for SPRB

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.